The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S21-S27 , October 2007

Daptomycin in the Treatment of Bacteremia

The results of this study were presented at the 43rd Annual Meeting of the Infectious Diseases Society of America; October 6–9, 2005; San Francisco, California.

  • George Sakoulas, MD

      Affiliations

    • New York Medical College, Valhalla, New York, USA
    • ,
  • Yoav Golan, MD, MS

      Affiliations

    • Tufts New England Medical Center, Boston, Massachusetts, USA
    • ,
  • Kenneth C. Lamp, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA.
    • Corresponding Author InformationRequests for reprints should be addressed to Kenneth C. Lamp, PharmD, Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, Massachusetts 02421.
    • ,
  • Lawrence V. Friedrich, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA.
    • ,
  • Rene Russo, PharmD

      Affiliations

    • Cubist Pharmaceuticals, Inc., Lexington, Massachusetts, USA.

References 

  1. Linden PK. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance. Am J Med. 1998;104:24S–33S
  2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317
  3. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53–59
  4. Bhavnani SM, Drake JA, Forrest A, et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis. 2000;36:145–158
  5. Lodise TP, McKinnon PS, Tam VH, Rybak MJ. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002;34:922–929
  6. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis. 2005;191:588–595
  7. Cosgrove SE, Qi Y, Kaye KS, Harbart S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166–174
  8. Smith TL, Pearson ML, Wilcox KR, et al. Glycopeptide-Intermediate Staphylococcus aureus Working Group Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med. 1999;340:493–501
  9. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(suppl 1):S25–S34
  10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42:2398–2402
  11. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis. 2006;42(suppl 1):S13–S24
  12. Rhee KY, Gardiner DF, Charles M. Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux. Clin Infect Dis. 2005;40:1705–1706
  13. Kapadia M, Coyle E, Prince R, Rolston K. Declining in vitro activity of vancomycin against Staphylococcus aureus isolates from cancer patients. Presented at the 45th Annual Meeting of Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) In: Washington, DC: American Society for Microbiology; 2005;p. 168;Abstract E-807
  14. Fowler VG, Boucher HW, Corey R, et al. S. aureus Endocarditis and Bacteremia Study Group Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  15. Rolston KVI, Segreti JA, Lamp KC, Friedrich LV. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 2007;120(10A):S4–S5
  16. Fowler VG, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293:3012–3021
  17. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–1554
  18. Cubicin (daptomycin for injection). [prescribing information] Lexington, MA: Cubist Pharmaceuticals, Inc; 2006;
  19. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006;26:347–352
  20. Furuya EY, Kubin C, Yin M, Lowy F, Della-Latta P, Hammer S. Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia. [abstract K-2116]. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) In: Washington, DC: American Society for Microbiology; 2005;p. 379
  21. Okoye OP, Mushatt D. Daptomycin: efficacy and safety of use in treatment of gram-positive infections. Presented at the 41st Annual Meeting Infectious Diseases Society of America (IDSA) In: Alexandria, VA: Infectious Diseases Society of America; 2005;p. 121

 Please see Author Disclosure section at the end of this article.

PII: S0002-9343(07)00661-4

doi: 10.1016/j.amjmed.2007.07.012

The American Journal of Medicine
Volume 120, Issue 10, Supplement 1 , Pages S21-S27 , October 2007

Article Tools